Advertisement

Hypertension in End-Stage Renal Disease: Dialysis

  • Franz SchaeferEmail author
Reference work entry
First Online:

Abstract

Hypertension and left ventricular hypertrophy are highly prevalent in the pediatric dialysis population. Ambulatory or home blood pressure monitoring is required to obtain prognostically relevant information about a patient’s blood pressure status. Volume status is the primary determinant of blood pressure in dialysis patients; the clinical relevance of additional pathogenic mechanisms such as sympathetic hyperactivity is controversial. The most important measure to maintain normal blood pressure is achievement of the dry weight, which can be facilitated by the use of bioimpedance analysis and intradialytic blood volume monitoring. Dietary salt restriction and avoidance of net salt uptake during dialysis is key to maintain fluid balance. Extended hemodialysis schedules efficiently normalize blood pressure and reverse left ventricular hypertrophy in patients who cannot maintain fluid balance under standard thrice weekly hemodialysis. Pharmacotherapy of hypertension should only be reserved to patients with persistent hypertension despite adequate volume status. The preferable first-line antihypertensive drug class is currently unclear; head-to-head comparative trials are urgently needed.

Keywords

Left ventricular hypertrophy ABPM Blood volume monitoring 
This is a preview of subscription content, log in to check access.

References

  1. Agarwal R (2010) Blood pressure and mortality among hemodialysis patients. Hypertension 55:762–768PubMedPubMedCentralGoogle Scholar
  2. Agarwal R, Lewis RR (2001) Prediction of hypertension in chronic hemodialysis patients. Kidney Int 60:1982–1989PubMedGoogle Scholar
  3. Agarwal R, Sinha AD (2009) Cardiovascular protection with antihypertensive drugs in dialysis patients in dialysis patients: systematic review and meta-analysis. Hypertension 53:860–866PubMedPubMedCentralGoogle Scholar
  4. Agarwal R, Andersen MJ, Bishu K, Saha C (2006a) Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. Kidney Int 69:900–906PubMedGoogle Scholar
  5. Agarwal R, Brim NJ, Mahenthiran J, Andersen MJ, Saha C (2006b) Out-of-hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. Hypertension. 47:62–68PubMedGoogle Scholar
  6. Agarwal R, Peixoto AJ, Santos SF, Zoccali C (2006c) Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol 1:389–398PubMedGoogle Scholar
  7. Agarwal R, Andersen MJ, Light RP (2008) Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am J Nephrol 28:210–217PubMedGoogle Scholar
  8. Agarwal R, Bouldin JM, Light RP, Garg A (2011) Inferior vena cava diameter and left atrial diameter measure volume but not dry weight. Clin J Am Soc Nephrol 6:1066–1072PubMedPubMedCentralGoogle Scholar
  9. Agarwal R, Satyan S, Alborzi P, Light RP, Tegegne GG, Mazengia HS, Yigazu PM (2009) Home blood pressure measurements for managing hypertension in hemodialysis patients. Am J Nephrol 30:126–134PubMedPubMedCentralGoogle Scholar
  10. Alborzi P, Patel N, Agarwal R (2007) Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2:1228–1234PubMedGoogle Scholar
  11. Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ, Salvador M, Chamontin B (2000) Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 57:2485–2491PubMedGoogle Scholar
  12. Anderstam B, Katzarski K, Bergström J (1997) Serum levels of NO, NG-dimethyl-L-Arginine, a potential endogenous nitic oxide inhibitor in dialysis patients. J Am Soc Nephrol 8:1437–1442PubMedGoogle Scholar
  13. Arbor Research Collaborative for Health. The DOPPS Practice Monitor. www.dopps.org/DPM/. Accessed 30 Jan 2017.
  14. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG (2002) Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 20:3–9PubMedGoogle Scholar
  15. Bakkaloglu SA, Borzych D, Soo Ha I, Serdaroglu E, Büscher R, Salas P, Patel H, Drozdz D, Vondrak K, Watanabe A, Villagra J, Yavascan O, Valenzuela M, Gipson D, Ng KH, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network (2011) Cardiac geometry in children receiving chronic peritoneal dialysis: findings from the International Pediatric Peritoneal Dialysis Network (IPPN) registry. Clin J Am Soc Nephrol 6:1926–1933PubMedPubMedCentralGoogle Scholar
  16. Bakris GL, Hart P, Ritz E (2006) Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905–1913PubMedGoogle Scholar
  17. Bakris GL, Burkart JM, Weinhandl ED, McCullough PA, Kraus MA (2016) Intensive hemodialysis, blood pressure, and antihypertensive medication use. Am J Kidney Dis 68:S15–S23PubMedGoogle Scholar
  18. Bansal N, McCulloch CE, Rahman M, Kusek JW, Anderson AH, Xie D, Townsend RR, Lora CM, Wright J, Go AS, Ojo A, Alper A, Lustigova E, Cuevas M, Kallem R, Hsu CY, Study Investigators CRIC (2015) Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension 65:93–100PubMedGoogle Scholar
  19. Bayya A, Rubinger D, Linton DM, Sviri S (2011) Evaluation of intradialytic hypotension using impedance cardiography. Int Urol Nephrol 43:855–864PubMedGoogle Scholar
  20. Bircan Z, Duzova A, Cakar N, Bayazit AK, Elhan A, Tutar E, Ozcakar ZB, Ucar T, Kargin E, Erdem S, Karagöz T, Babaoglu A, Sancak B, Noyan A, Soylemezoglu O, Bakkaloglu A, Yalcinkaya F (2010) Predictors of left ventricular hypertrophy in children on chronic peritoneal dialysis. Pediatr Nephrol 25:1311–1318PubMedGoogle Scholar
  21. Borzych D, Bakkaloglu SA, Zaritsky J, Suarez A, Wong W, Ranchin B, Qi C, Szabo AJ, Coccia PA, Harambat J, Mitu F, Warady BA, Schaefer F (2011) International Pediatric Peritoneal Dialysis Network. Defining left ventricular hypertrophy in children on peritoneal dialysis. Clin J Am Soc Nephrol 6:1934–1943PubMedPubMedCentralGoogle Scholar
  22. Borzych-Duzalka D, Bilginer Y, Ha IS, Bak M, Rees L, Cano F, Munarriz RL, Chua A, Pesle S, Emre S, Urzykowska A, Quiroz L, Ruscasso JD, White C, Pape L, Ramela V, Printza N, Vogel A, Kuzmanovska D, Simkova E, Müller-Wiefel DE, Sander A, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network (IPPN) Registry (2013) Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24:665–676PubMedPubMedCentralGoogle Scholar
  23. Candan C, Sever L, Civilibal M, Caliskan S, Arisoy N (2009) Blood volume monitoring to adjust dry weight in hypertensive pediatric hemodialysis patients. Pediatr Nephrol 24:581–587PubMedGoogle Scholar
  24. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S (1997) Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30:659–664PubMedGoogle Scholar
  25. Chaudhuri A, Sutherland SM, Begin B, Salsbery K, McCabe L, Potter D, Alexander SR, Wong CJ (2011) Role of twenty-four-hour ambulatory blood pressure monitoring in children on dialysis. Clin J Am Soc Nephrol 6:870–876PubMedPubMedCentralGoogle Scholar
  26. Chavers BM, Solid CA, Daniels FX, Chen SC, Collins AJ, Frankenfield DL, Herzog CA (2009) Hypertension in pediatric long-term hemodialysis patients in the United States. Clin J Am Soc Nephrol 4:1363–1369PubMedPubMedCentralGoogle Scholar
  27. Converse RLJ, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F et al (1992) Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912–1918PubMedGoogle Scholar
  28. Correa-Rotter R, Cueto-Manzano A (2001) The problem of the high transporter: is survival decreased? Perit Dial Int. 21(Suppl 3):S75–S79PubMedGoogle Scholar
  29. Drechsler C, Ritz E, Tomaschitz A, Pilz S, Schönfeld S, Blouin K, Bidlingmaier M, Hammer F, Krane V, März W, Allolio B, Fassnacht M, Wanner C (2013) Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. Eur Heart J 34:578–587PubMedGoogle Scholar
  30. Fabian Velasco R, Lagunas Muñoz J, Sanchez Saavedra V, Mena Brito Trejo JE, Qureshi AR, García-López E, Divino Filho JC (2008) Automated peritoneal dialysis as the modality of choice: a single-center, 3-year experience with 458 children in Mexico. Pediatr Nephrol 23:465–471PubMedGoogle Scholar
  31. Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Ibsen H, O'Brien E, Wang J, Staessen JA, International Database on Ambulatory Blood Pressure In Relation to Cardiovascular Outcomes Investigators (2010) Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 28:2036–2045PubMedGoogle Scholar
  32. Fischbach M, Terzic J, Laugel V, Dheu C, Menouer S, Helms P, Livolsi A (2004) Daily on-line haemodiafiltration: a pilot trial in children. Nephrol Dial Transplant 19:2360–2367PubMedGoogle Scholar
  33. Fischbach M, Schmitt CP, Shroff R, Zaloszyc A, Warady BA (2016) Increasing sodium removal on peritoneal dialysis: applying dialysis mechanics to the peritoneal dialysis prescription. Kidney Int 89:761–766PubMedGoogle Scholar
  34. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 47:186–192PubMedGoogle Scholar
  35. Georgianos PI, Agarwal R (2016) Epidemiologiy, diagnosis and management of hypertension among patients on chronic dialysis. Nat Rev Nephrol 12:636–647PubMedGoogle Scholar
  36. Goldstein SL, Silverstein DM, Leung JC, Feig DI, Soletsky B, Knight C, Warady BA (2008) Frequent hemodialysis with NxStage system in pediatric patients receiving maintenance hemodialysis. Pediatr Nephrol 23:129–135PubMedGoogle Scholar
  37. Ha IS, Yap HK, Munarriz RL, Zambrano PH, Flynn JT, Bilge I, Szczepanska M, Lai WM, Antonio ZL, Gulati A, Hooman N, van Hoeck K, Higuita LM, Verrina E, Klaus G, Fischbach M, Riyami MA, Sahpazova E, Sander A, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network Registry (2015) Risk factors for loss of residual renal function in children treated with chronic peritoneal dialysis. Kidney Int 88:605–613PubMedPubMedCentralGoogle Scholar
  38. Halbach SM, Martz K, Mattoo T, Flynn J (2012) Predictors of blood pressure and its control in pediatric patients receiving dialysis. J Pediatr 160:621–625PubMedGoogle Scholar
  39. Hatch M, Freel RW, Vaziri ND (1998) Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure. Am J Physiol 274(2 Pt 2):F275–F282PubMedGoogle Scholar
  40. Heerspink HJ et al (2009) Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 373:1009–1015PubMedPubMedCentralGoogle Scholar
  41. Inrig JK (2010) Antihypertensive agents in hemodialysis patients: a current perspective. Semin Dial 23:290–297PubMedPubMedCentralGoogle Scholar
  42. Jang JS, Kwon SK, Hy K (2011) Comparison of blood pressure control and left ventricular hypertrophy in patients on Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD). Electrolyte Blood Press 9:16–22PubMedPubMedCentralGoogle Scholar
  43. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P (2011) Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction. Semin Dial 24:327–337PubMedGoogle Scholar
  44. Kayikcioglu M, Tumuklu M, Ozkahya M, Ozdogan O, Asci G, Duman S, Toz H, Can LH, Basci A, Ok E (2009) The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant 24:956–962PubMedGoogle Scholar
  45. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ (2003) Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 14:425–430PubMedGoogle Scholar
  46. Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD (2002) Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 112:110–114PubMedGoogle Scholar
  47. Kramer AM, van Stralen KJ, Jager KJ, Schaefer F, Verrina E, Seeman T, Lewis MA, Boehm M, Simonetti GD, Novljan G, Groothoff JW (2011) Demographics of blood pressure and hypertension in children on renal replacement therapy in Europe. Kidney Int 80:1092–1098PubMedGoogle Scholar
  48. Krause I, Birk E, Davidovits M, Cleper R, Blieden L, Pinhas L, Gamzo Z, Eisenstein B (2001) Inferior vena cava diameter: a useful method for estimation of fluid status in children on haemodialysis. Nephrol Dial Transplant 16:1203–1206PubMedGoogle Scholar
  49. Lin JJ, Mitsnefes MM, Smoyer WE, Valentini RP (2009) Antihypertensive prescription in pediatric dialysis: a practitioner survey by the Midwest Pediatric Nephrology Consortium study. Hemodial Int 13:307–315PubMedGoogle Scholar
  50. Lin C, Zhang Q, Zhang H, Lin A (2016) Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study. J Clin Hypertens (Greenwich) 18:121–128Google Scholar
  51. Lingens N, Soergel M, Loirat C, Busch C, Lemmer B, Schärer K (1995) Ambulatory blood pressure monitoring in paediatric patients treated by regular haemodialysis and peritoneal dialysis. Pediatr Nephrol 9:167–172PubMedGoogle Scholar
  52. London GM, Marchais SJ, Guerin AP, Metivier F, Safar ME, Fabiani F, Froment L (1990) Salt and water retention and calcium blockade in uremia. Circulation 82:105–113PubMedGoogle Scholar
  53. Maduell F, Navarro V (2000) Dietary salt intake and blood pressure controlin hemodialysis patients. Nephrol Dial Transplant 15:2063PubMedGoogle Scholar
  54. Martin RS, Panese S, Virginillo M, Gimenez M, Litardo M, Arrizurieta E, Hayslett JP (1986) Increased secretion of potassium in the rectum of humans with chronic renal failure. Am J Kidney Dis 8:105–110PubMedGoogle Scholar
  55. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N (2014) Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 63:528–536PubMedGoogle Scholar
  56. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243–1248PubMedGoogle Scholar
  57. Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578–585PubMedPubMedCentralGoogle Scholar
  58. Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF (2001) Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr Nephrol 16:318–323PubMedGoogle Scholar
  59. Mitsnefes MM, Barletta GM, Dresner IG, Chand DH, Geary D, Lin JJ, Patel H (2006) Severe cardiac hypertrophy and long-term dialysis: the Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 21:1167–1170PubMedGoogle Scholar
  60. Mitsnefes MM, Laskin BL, Dahhou M, Zhang X, Foster BJ (2013) Mortality risk among children initially treated with dialysis for end-stage kidney disease, 1990-2010. JAMA 309:1921–1929PubMedPubMedCentralGoogle Scholar
  61. Moissl U, Arias-Guillén M, Wabel P, Fontseré N, Carrera M, Campistol JM, Maduell F (2013) Bioimpedance-guided fluid management in hemodialysis patients. Clin J Am Soc Nephrol 8:1575–1582PubMedPubMedCentralGoogle Scholar
  62. National Kidney Foundation (2005) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45(4 suppl 3):S1–S153Google Scholar
  63. Onofriescu M, Hogas S, Voroneanu L, Apetrii M, Nistor I, Kanbay M, Covic AC (2014) Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial. Am J Kidney Dis 64:111–118PubMedGoogle Scholar
  64. Patel HP, Goldstein SL, Mahan JD, Smith B, Fried CB, Currier H, Flynn JT (2007) A standard, noninvasive monitoring of hematocrit algorithm improves blood pressure control in pediatric hemodialysis patients. Clin J Am Soc Nephrol 2:252–257PubMedGoogle Scholar
  65. Peters CD, Kjaergaard KD, Jensen JD, Christensen KL, Strandhave C, Tietze IN, Novosel MK, Bibby BM, Jensen LT, Sloth E, Jespersen B (2014) No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. Kidney Int 86:625–637PubMedGoogle Scholar
  66. Pietilä-Effati PM, Salmela AK, Niemi RT, Ylitalo AS, Koistinen MJ (2016) Renal sympathetic denervation in treating drug-resistant hypertension in a patient on hemodialysis. J Hypertens 34:368–370PubMedGoogle Scholar
  67. Rahman M, Griffin V, Kumar A, Manzoor F, Wright JT Jr, Smith MC (2002) A comparison of standardized versus “usual” blood pressure measurements in hemodialysis patients. Am J Kidney Dis 39:1226–1230PubMedGoogle Scholar
  68. Sadowski RH, Allred EN, Jabs K (1993) Sodium modeling ameliorates intradialytic and interdialytic symptoms in young hemodialysis patients. J Am Soc Nephrol. 4:1192–1198PubMedGoogle Scholar
  69. Sanghavi S, Whiting S, Uribarri J (2013) Potassium balance in dialysis patients. Semin Dial 26:597–603PubMedGoogle Scholar
  70. Scavarda VT, Pinheiro AC, Costa SD, de Andrade ZM, Carvalhaes JT, Campos O, Carvalho AC, Moises VA (2014) Children with chronic renal disease undergoing dialysis or conservative treatment--differences in structural and functional echocardiographic parameters. Echocardiography. 31:1131–1137PubMedGoogle Scholar
  71. Schaefer F, Doyon A, Azukaitis K, Bayazit A, Canpolat N, Duzova A, Niemirska A, Sözeri B, Thurn D, Anarat A, Ranchin B, Litwin M, Caliskan S, Candan C, Baskin E, Yilmaz E, Mir S, Kirchner M, Sander A, Haffner D, Melk A, Wühl E, Shroff R (2017) Querfeld U; 4C Study Consortium. Cardiovascular Phenotypes in Children with CKD: The 4C Study. Clin J Am Soc Nephrol 12:19–28PubMedGoogle Scholar
  72. Schmidt RJ, Domico J, Samsell LS, Yokota S, Tracy C, Sorkin MI et al (1999a) Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 34:228–234PubMedPubMedCentralGoogle Scholar
  73. Schmidt RJ, Yokota S, Tracy C, Sorkin MI, Baylis C (1999b) Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol 276:794–797Google Scholar
  74. Shafi T, Sozio SM, Luly J, Bandeen-Roche KJ, St Peter WL, Ephraim PL, McDermott A, Herzog CA, Crews DC, Scialla JJ, Tangri N, Miskulin DC, Michels WM, Jaar BG, Zager PG, Meyer KB, Wu AW (2017) Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices. Medicine (Baltimore) 96:e5924Google Scholar
  75. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T (2002) Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 90:256–261PubMedGoogle Scholar
  76. Sinha MD, Tibby SM, Rasmussen P, Rawlins D, Turner C, Dalton RN, Reid CJ, Rigden SP, Booth CJ, Simpson JM (2011) Blood pressure control and left ventricular mass in children with chronic kidney disease. Clin J Am Soc Nephrol 543–551PubMedGoogle Scholar
  77. Song JH, Park GH, Lee SY, Lee SW, Lee SW, Kim MJ (2005) Effect of sodium balance and the combination of ultrafiltration profile during sodium profiling hemodialysis on the maintenance of the quality of dialysis and sodium and fluid balances. J Am Soc Nephrol 16:237–246PubMedGoogle Scholar
  78. Sorof JM (1999) Ambulatory blood pressure monitoring in pediatric end-stage renal disease: Chronic dialysis and transplantation. Blood Press Monit 4:171–174PubMedGoogle Scholar
  79. Sorof JM, Brewer ED, Portmann RJ (1999) Ambulatory blood pressure monitoring and interdialytic weight gain in children receiving chronic hemodialysis. Am J Kidney Dis 33:667–674PubMedGoogle Scholar
  80. Thumfart J, Hilliger T, Stiny C, Wagner S, Querfeld U, Müller D (2015) Is peritoneal dialysis still an equal option? Results of the Berlin pediatric nocturnal dialysis program. Pediatr Nephrol 30:1181–1187PubMedGoogle Scholar
  81. Tkaczyk M, Nowicki M, Balasz-Chmielewska I, Boguszewska-Baczkowska H, Drozdz D, Kollataj B et al (2006) Hypertension in dialysed children: the prevalence and therapeutic approach in Poland--a nation wide survey. Nephrol Dial Transplant 21:736–742PubMedGoogle Scholar
  82. van Stralen KJ, Krischock L, Schaefer F, Verrina E, Groothoff JW, Evans J, Heaf J, Ivanov D, Kostic M, Maringhini S, Podracká L, Printza N, Pundziene B, Reusz GS, Vondrak K, Jager KJ, Tizard EJ, ESPN/ERA-EDTA Registry (2012) Prevalence and predictors of the sub-target Hb level in children on dialysis. Nephrol Dial Transplant 27:3950–3957PubMedGoogle Scholar
  83. Vujicić B, Mikolasević I, Racki S, Orlić L, Ljutić D, Bubić I (2013) BCM—body composition monitor: a new tool for the assessment of volume-dependent hypertension in patients on maintenance haemodialysis. Coll Antropol 37:815–819PubMedGoogle Scholar
  84. Warren DJ, Ferris TF (1970) Renin secretion in renal hypertension. Lancet 1:159–162PubMedGoogle Scholar
  85. Wauters JP, Waeber B, Brunner HR, Guignard JP, Turini GA, Gavras H (1981) Uncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtraction. Clin Nephrol 16:86–92PubMedGoogle Scholar
  86. Weir MA, Dixon SN, Fleet JL, Roberts MA, Hackam DG, Oliver MJ, Suri RS, Quinn RR, Ozair S, Beyea MM, Kitchlu A, Garg AX (2015) β-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 26:987–996PubMedGoogle Scholar
  87. Wetmore JB, Mahnken JD, Phadnis MA, Ellerbeck EF, Shireman TI (2015) Relationship between calcium channel blocker class and mortality in dialysis. Pharmacoepidemiol Drug Saf 24:1249–1258PubMedPubMedCentralGoogle Scholar
  88. White CM (1998) Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 18:588–599PubMedGoogle Scholar
  89. Wühl E, Fusch C, Schärer K, Mehls O, Schaefer F (1996) Assessment of total body water in paediatric patients on dialysis. Nephrol Dial Transplant 11:75–80PubMedGoogle Scholar
  90. Zaloszyc A, Schaefer B, Schaefer F, Krid S, Salomon R, Niaudet P, Schmitt CP, Fischbach M (2013) Hydration measurement by bioimpedance spectroscopy and blood pressure management in children on hemodialysis. Pediatr Nephrol 28:2169–2177PubMedGoogle Scholar
  91. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent I, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21PubMedGoogle Scholar
  92. Zazgornik J, Biesenbach G, Janko O, Gross C, Mair R, Brücke P, Debska-Slizien A, Rutkowski B (1998) Bilateral nephrectomy: the best, but often overlooked, treatment for refractory hypertension in hemodialysis patients. Am J Hypertens 11(11 Pt 1):1364–1370PubMedGoogle Scholar
  93. Zoccali C, Mallamaci F (2014) Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality? Kidney Int 86:469–471PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Division of Pediatric Nephrology CenterPediatrics and Adolescent MedicineHeidelbergGermany

Section editors and affiliations

  • Joseph T. Flynn
    • 1
    • 2
  1. 1.Department of PediatricsUniversity of Washington School of MedicineSeattleUSA
  2. 2.Division of NephrologySeattle Children’s HospitalSeattleUSA

Personalised recommendations

Cite entry